CompletedNot Applicable

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

United States, Australia, Canada174 participantsStarted 2005-05-30

Plain-language summary

This research study is collecting and storing tissue samples from patients with rare or cutaneous non-Hodgkin lymphoma. Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.

Who can participate

Age range

21 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of NHL * Any histology, except for Burkitt or Burkitt-like, diffuse large B-cell, anaplastic large cell, or lymphoblastic lymphoma * Primary CNS, primary cutaneous NHL, or lymphoproliferative diseases of any histology allowed * Pathological specimen from site not treated within the past 6 months * Must have specimens available * At least 6 months since prior chemotherapy irradiation to study lesion * At least 2 weeks since prior steroids

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Clinical features, treatment, and outcomes

Timeframe: Up to 5 years

Pathologic and biologic features of these diseases, including molecular diagnostics and flow cytometry

Timeframe: Up to 5 years

Establishment of a bank of these pathologically reviewed diseases and make specimens of blood and tissue available to qualified researchers

Timeframe: Up to 5 years

Sub-groups of these diseases that could be targeted for future biologic, pathologic, or therapeutic studies

Timeframe: Up to 5 years

Trial details

NCT IDNCT01000753

SponsorChildren's Oncology Group

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2007-06-01

View on ClinicalTrials.gov More Adult Immunoblastic Lymphoma trials

Who can participate

Age range

21 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Clinical features, treatment, and outcomes

Timeframe: Up to 5 years

Pathologic and biologic features of these diseases, including molecular diagnostics and flow cytometry

Timeframe: Up to 5 years

Establishment of a bank of these pathologically reviewed diseases and make specimens of blood and tissue available to qualified researchers

Timeframe: Up to 5 years

Sub-groups of these diseases that could be targeted for future biologic, pathologic, or therapeutic studies

Timeframe: Up to 5 years